司帕沙星治疗耐多药肺结核近期疗效分析

目的　评价司帕沙星对耐多药肺结核 (MDR-PTB)的疗效。方法 104例MDR-PTB患者随机分为两组，以氧氟沙星作为对照。治疗组52例采用3SHRZE+SPLX/9HRE+SPLX方案治疗，对照组采用3SHRZE+OFLX9HRE+OFLX方案治疗。结果 疗程结束时，治疗组痰菌阴转率92.3%，明显高于对照组69.2% (P＜0.05)；治疗2个月时治疗组痰菌阴转阴率与对照组相比有显著性差异(P＜0.01)。结论 司帕沙星是目前氟喹诺酮类中治疗MDR-PTB较为有效的药物。

The therapeutic effect of sparfloxacin on multidrug resistant pulmonary tuberculosis

Objective To evaluate the therapeutic effect of sparfloxacin (SPLX)on multidrug resistant pulmonary tuberculosis (MDR-PTB).Methods 104 cases of MDR-PTB were allocated at random pair to two groups,using domestic ofloxacin (OFLX) as comparison.52 cases were treated with the regimen of 3SHRZE SPLX/9HRE SPLX.52 cases were treated with the regimen of 3SHRZE OFLX/9HRE OFLX.Results At the end of treatment,the sputum negative conversion rates of treatment group were 92.3%,while the rates of control group were 69.2%, P <0.05,after two months treatment the difference of the sputum negative conrersion rate in the treatment group was statistically significant when compared with the control group (P<0.01) .Conclusion Sparfloxacin is an effective drug in treating patients with MDR-PTB among other quinolones.